Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth

On June 4, Reuters reported a national justice ‌ruled that Abbott Laboratories (NYSE:ABT) indispensable look a projected class-action suit alleging it misled consumers by selling PediaSure Grow & Gain drinks arsenic "clinically proven" to assistance children grow.

US District Judge Paul Engelmayer said labeling featuring a giraffe and ruler-like marks could pb consumers to construe "grow" arsenic tallness gain, portion "gain" implied weight. Hence, the claims volition proceed, and Abbott Laboratories (NYSE:ABT) indispensable defend.

In a 75-page decision, Engelmayer noted jurors could find the firm's commercials reinforced that message, citing an advertisement showing a lad comparing himself to taller peers.

The corp said its labeling is "appropriate" and backed by evidence, maintaining PediaSure supports children's maturation and development.

Plaintiff Joanne Noriega said her grandson remained abbreviated aft a twelvemonth of regular usage but became overweight, portion her lawyer James Denlea said helium welcomed the ruling.

Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells healthcare products. It operates done Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices segments.

While we admit the imaginable of ABT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.